Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13797 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Amr M Fahmi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Warfarin, Anticoagulants, International Normalized Ratio. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Different dosing strategies exist to initiate warfarin, most commonly fixed warfarin dosing (FWD), clinical warfarin dosing (CWD), and genetic‐guided warfarin dosing (GWD). Landmark trials have shown GWD to be superior when compared to FWD in the EU‐PACT trial or CWD in the GIFT trial. COAG trial did not show differences between GWD and CWD. We aim to compare the anticoagulation quality outcomes of CWD and FWD. This is a prospective cohort study with a retrospective comparator. Recruited subjects in the CWD (prospective) arm were initiated on warfarin according to the clinical dosing component of the algorithm published in www.warfarindosing.org . The primary efficacy outcome was the percentage time in the therapeutic range (PTTR) from day 3 to 6 till day 28 to 35. The study enrolled 122 and 123 patients in the CWD and FWD, respectively. The PTTR did not differ statistically between CWD and FWD (62.2 ± 26.2% vs. 58 ± 25.4%, p = 0.2). There was also no difference between both arms in the percentage of visits with extreme subtherapeutic international normalized ratio (INR) (4; 7.7 ± 14.7% vs. 7.5 ± 12.4%, p = 0.92). We conclude that CWD did not improve the anticoagulation quality parameters compared to the FWD method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
- College of Pharmacy, Qatar University, Doha, Qatar.
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, USA.
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
- Department of Cardiology, AlWakra Hospital, Hamad Medical Corporation, AlWakra, Qatar.
ORCID-Profile: Amr M Fahmi, Ahmed El Bardissy, Mohamed Omar Saad, Mohamed Nabil Elshafei, Loulia Bader, Ahmed Mahfouz, Mohamed Kasem, Osama Abdelsamad, Abdelnasser Elzouki, Christina L Aquilante, Fatima Mraiche, Ihab El Madhoun, Abdulrahman Arabi, Eman Alhmoud, Hazem Elewa
Zitieren
APA
Fahmi, A. M., El Bardissy, A., Saad, M. O., Elshafei, M. N., Bader, L., Mahfouz, A., Kasem, M., Abdelsamad, O., Elzouki, A., Aquilante, C. L., Mraiche, F., Soaly, E., El Madhoun, I., Asaad, N., Arabi, A., Alhmoud, E., & Elewa, H. (2024). Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial). Clinical and Translational Science. https://doi.org/10.1111/cts.13797
Vancouver
Fahmi AM, El Bardissy A, Saad MO, Elshafei MN, Bader L, Mahfouz A, et al. Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial). Clinical and Translational Science. 2024. doi:10.1111/cts.13797
BibTeX
@article{Fahmi2024,
author = {Fahmi, Amr M and El Bardissy, Ahmed and Saad, Mohamed Omar and Elshafei, Mohamed Nabil and Bader, Loulia and Mahfouz, Ahmed and Kasem, Mohamed and Abdelsamad, Osama and Elzouki, Abdelnasser and Aquilante, Christina L and Mraiche, Fatima and Soaly, Ezeldin and El Madhoun, Ihab and Asaad, Nidal and Arabi, Abdulrahman and Alhmoud, Eman and Elewa, Hazem},
title = {Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13797}
}
EUVIMED